Rhumbline Advisers Poseida Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 104,500 shares of PSTX stock, worth $285,285. This represents 0.0% of its overall portfolio holdings.
Number of Shares
104,500
Previous 97,012
7.72%
Holding current value
$285,285
Previous $283,000
5.3%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PSTX
# of Institutions
98Shares Held
38.5MCall Options Held
377KPut Options Held
22.2K-
Pentwater Capital Management LP Naples, FL5.98MShares$16.3 Million0.18% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$13.4 Million0.0% of portfolio
-
Silverarc Capital Management, LLC3.69MShares$10.1 Million2.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.66MShares$10 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$5.99 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $234M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...